Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial
about
Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)Diagnostics techniques in nonmuscle invasive bladder cancerRecent advances in the diagnosis and treatment of bladder cancer.Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.Immune therapies in non-muscle invasive bladder cancer.Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer.Trial Watch: Toll-like receptor agonists for cancer therapy.[Urine cytology - update 2013. A systematic review of recent literature].Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.The contemporary role and impact of urine-based biomarkers in bladder cancer.The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guérin therapy for bladder cancer: A diagnostic meta-analysis and systematic review
P2860
Q26744756-F7354E18-C397-4B1B-AA74-4C1EFEF7AAEFQ26775987-D2A17D84-AA8C-45F4-8F26-8DFF9882D6B9Q34552725-0F1C6D8A-0587-4FD0-9D59-E9DCAB45ABA9Q36338886-96F8ABF7-FE2A-4D34-8527-771CD89FD111Q36404440-9C92CA08-6B8A-427B-BE8C-8584B0CBD303Q37705271-55B20CA4-FA1B-493D-B4B7-3C462B231E83Q37722013-99382751-8234-4DBD-9264-6FABDBD03BE4Q38372571-4C45A158-123E-49AC-B53F-FD2FD8084254Q40893287-6E1B03C1-74CA-4DC6-8CFA-A219CDACC551Q41597185-DBFBF6D4-C2FA-4BDA-AFF5-20928CA33585Q42649782-70D08BC3-1E44-48CD-AB1E-A3BFBEB461F7Q42969291-DDA3FBD6-04E6-42BA-BCC2-4D741EEA4782Q45139625-0B7189EC-3A33-4552-ABF8-DD6D56B10BB7Q46851166-3641E00C-87DF-456D-A61A-1C085A26FF93Q47721208-127E264F-0720-4FE8-A690-4CE1A2DBA87BQ58759162-5523AC19-DDF3-4D3B-8ECE-35EB5791B2EB
P2860
Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Use of fluorescence in situ hy ...... results of a prospective trial
@ast
Use of fluorescence in situ hy ...... results of a prospective trial
@en
type
label
Use of fluorescence in situ hy ...... results of a prospective trial
@ast
Use of fluorescence in situ hy ...... results of a prospective trial
@en
prefLabel
Use of fluorescence in situ hy ...... results of a prospective trial
@ast
Use of fluorescence in situ hy ...... results of a prospective trial
@en
P2093
P2860
P1476
Use of fluorescence in situ hy ...... results of a prospective trial
@en
P2093
Abha Khanna
Ashish M Kamat
Colin P Dinney
Fabrizio Messetti
Graciela Noguera Gonzalez
H Barton Grossman
Rian J Dickstein
Roosevelt Anderson
Ruth L Katz
Shanna M Pretzsch
P2860
P304
P356
10.1016/J.JURO.2011.10.144
P407
P577
2012-01-15T00:00:00Z